Product Reports Resources Pricing Login Book a demo

GoodRx

Biotech & Life Sciences · Santa Monica, United States · Founded 2011 · IPO 2020

Provides health consumers with convenient and affordable prescription drugs

Valuation $1.35B
Revenue $776M
EBITDA $238M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

12 investors on GoodRx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 10 investors entered at this stage
Dawn Lepore
Soma Capital
Lerer Hippeau
Francisco Partners
Spectrum Equity
Upfront Ventures
SV Angel
Highland Capital Partners
Michael Ovitz
Founders Fund
Series B+ 2 investors entered at this stage
Silver Lake Partners
TCV

GoodRx mafia

Startups founded by GoodRx alumni

Former GoodRx employees who went on to start their own companies. Sorted by Dealroom signal score.

Trial LibraryEst. 2022
SBStephen BuckUnited States
Signal score89
ExceedsEst. 2024
MHMark HullUnited States
Signal score63
Ask Alex LabsEst. 2022
Bryan PollardUnited States
Signal score61
Dash EnergyEst. 2020
Bret HarrisUnited States
Signal score58
Kin HealthEst. 2025
Kyle AlwynUnited States
Signal score52

Book a demo to explore the full alumni network →

Global footprint

Where GoodRx has talent and traffic

Workforce by country
20 countries with
team presence
🇺🇸 United States95.7%
🇮🇳 India0.8%
🇧🇷 Brazil0.8%
🇵🇱 Poland0.2%
🇫🇷 France0.1%
Top 5 of 20 shown
Web traffic by country
20M monthly visits
across markets
🇺🇸 United States85.2%
🇨🇦 Canada4%
🇮🇳 India2.7%
🇦🇺 Australia1.7%
🇵🇭 Philippines0.7%
Top 5 markets shown

Talent graph

The shape of GoodRx's talent

Dealroom maps GoodRx's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 standout operatorsDealroom-flagged across the org
33 AI specialistsincl. 5 core researchers
1,074 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock GoodRx's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$340k patent portfolio · 3 active families

Estimated portfolio value
$340k
0.03% of market cap · comparable to top peer LetsGetChecked ($403k)
3 active patent families
Where GoodRx innovates DatabaseDrug pricesDrug productMedical educationMedication information

Where GoodRx concentrates vs peers

Each axis is a top-10 topic across GoodRx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

GoodRx's 7 investments and acquisitions.

Every disclosed deal where GoodRx appeared as a backer or acquirer, 2012–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

7 deals across GoodRx's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where GoodRx deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        GoodRx's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        7 of 7 deals

        Market sentiment

        What the market is saying about GoodRx

        An AI-synthesized read of the highest-engagement posts about GoodRx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See GoodRx on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles